PMID- 25830867
OWN - NLM
STAT- MEDLINE
DCOM- 20170214
LR  - 20220321
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Print)
IS  - 1075-2765 (Linking)
VI  - 23
IP  - 6
DP  - 2016 Nov/Dec
TI  - Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS 
      Trials in Patients With Acute Coronary Syndromes.
PG  - e1876-e1889
AB  - Cross-trial comparisons are typically inappropriate as there are often numerous 
      differences in study designs, populations, end points, and loading doses of the 
      study drugs. These differences are clearly reflected in the most recent updates 
      to the European Society of Cardiology (ESC) non-ST elevation acute coronary 
      syndrome (NSTE-ACS) and ST elevation myocardial infarction (STEMI) guidelines, 
      which include recommendations for the use of the antiplatelet agents ticagrelor, 
      prasugrel, and clopidogrel, based in part on results from the TRial to assess 
      Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with 
      prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38, TaRgeted 
      platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute 
      Coronary Syndromes (TRILOGY-ACS) and PLATelet inhibition and patient Outcomes 
      (PLATO) trials. Here, we describe each of these trials in detail and explain the 
      differences between them that make direct comparisons difficult. In conclusion, 
      this information, along with the current guidelines and recommendations, will 
      assist clinicians in deciding the most appropriate treatment pathway for their 
      patients with NSTE-ACS and STEMI.
FAU - Husted, Steen
AU  - Husted S
AD  - 1Department of Medicine, Hospital Unit West, Herning, Denmark; and 2Department of 
      Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
FAU - Boersma, Eric
AU  - Boersma E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Purinergic P2Y Receptor Antagonists)
RN  - A74586SNO7 (Clopidogrel)
RN  - G89JQ59I13 (Prasugrel Hydrochloride)
RN  - GLH0314RVC (Ticagrelor)
RN  - K72T3FS567 (Adenosine)
RN  - OM90ZUW7M1 (Ticlopidine)
SB  - IM
MH  - Acute Coronary Syndrome/*therapy
MH  - Adenosine/*analogs & derivatives/therapeutic use
MH  - Clopidogrel
MH  - Humans
MH  - Myocardial Infarction/*therapy
MH  - *Percutaneous Coronary Intervention
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prasugrel Hydrochloride/*therapeutic use
MH  - Proportional Hazards Models
MH  - Purinergic P2Y Receptor Antagonists/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ticagrelor
MH  - Ticlopidine/analogs & derivatives/therapeutic use
PMC - PMC5102280
COIS- Steen Husted has received speaker fees from AstraZeneca, Bayer, Boehringer 
      Ingelheim, Bristol-Myers Squibb, and Pfizer, and is an advisory board member for 
      AstraZeneca, Bayer, Bristol-Myers Squibb, and Pfizer. Eric Boersma has received 
      honorarium from Sanofi-Aventis, Medtronic, and Servier.
EDAT- 2015/04/02 06:00
MHDA- 2017/02/15 06:00
PMCR- 2016/11/09
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2017/02/15 06:00 [medline]
PHST- 2015/04/02 06:00 [entrez]
PHST- 2016/11/09 00:00 [pmc-release]
AID - AJT-201548 [pii]
AID - 10.1097/MJT.0000000000000237 [doi]
PST - ppublish
SO  - Am J Ther. 2016 Nov/Dec;23(6):e1876-e1889. doi: 10.1097/MJT.0000000000000237.